Morgan Stanley raises target for West Pharmaceutical stock to USD 400.00
Published on 10/05/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical Services (ISIN US9553061055) stood at EUR 325.50 at Lang & Schwarz on October 5, 2026 at 9:42 a.m. CEST, up 0.35 percent from the prior close of EUR 324.35. MarketScreener reported on September 22, 2026 that Morgan Stanley upgraded the stock to Overweight from Equal-Weight and raised its target from USD 365.00 to USD 400.00.
Target rises on durable growth
The analyst action gives West a valuation reference above the German-market quote, but the two prices use different currencies and are not directly comparable. The upgrade followed attention to the companys exposure to injectable drug packaging, biologics and GLP-1 treatments.
At the Wells Fargo Healthcare Conference on September 10, 2026, Investing.com reported that West raised full-year organic revenue growth guidance from 7 percent to 9 percent to 10 percent to 11 percent. Management also lifted margin expansion guidance to more than 200 basis points, approaching 250 basis points.
Second-quarter revenue jumps
MarketBeat reported that second-quarter 2026 revenue reached USD 872.30 million, up 13.80 percent from the same quarter a year earlier. Adjusted earnings per share came to USD 2.37 versus consensus of USD 2.08, a USD 0.29 difference, while fiscal 2026 adjusted earnings per share guidance stood at USD 8.85 to USD 9.05.
The numbers explain why the analyst case has shifted toward execution rather than simple recovery. West must convert demand in biologics and high-value components into sustained margin gains while managing the transition in its West Vantage business, a balance highlighted in the September conference discussion.
Results date sets the next test
West Pharmaceutical Services is scheduled to report its third-quarter 2026 results on October 22, 2026. The date is listed by Yahoo Finance alongside the NYSE quotation, and the next report will test whether the raised growth outlook can offset the near-term pressure described at the September conference.
On October 5, 2026, the Lang & Schwarz price was EUR 325.50 in trading at 9:42 a.m. CEST, plus 0.35 percent versus the Lang & Schwarz prior close of EUR 324.35 on October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of West Pharmaceutical stock.
West Pharmaceutical Services market data
- Company: West Pharmaceutical Services, Inc.
- ISIN: US9553061055
- Ticker: WST
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 5, 2026 at 9:42 a.m. CEST: EUR 325.50
- Change versus prior close: plus 0.35 percent
- Prior close Lang & Schwarz October 2, 2026: EUR 324.35
- Market capitalization: USD 25.7 billion as of October 2, 2026
- 52-week range: USD 223.83-386.00 as of October 2, 2026
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: S&P 500
- Next earnings date: October 22, 2026
